Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R; Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group. Doody RS, et al. Among authors: mohs r. N Engl J Med. 2014 Jan 23;370(4):311-21. doi: 10.1056/NEJMoa1312889. N Engl J Med. 2014. PMID: 24450890 Free article. Clinical Trial.
Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.
Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER. Farlow M, et al. Among authors: mohs r. Alzheimers Dement. 2012 Jul;8(4):261-71. doi: 10.1016/j.jalz.2011.09.224. Epub 2012 Jun 5. Alzheimers Dement. 2012. PMID: 22672770 Clinical Trial.
A phase 3 trial of semagacestat for treatment of Alzheimer's disease.
Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS; Alzheimer's Disease Cooperative Study Steering Committee; Siemers E, Sethuraman G, Mohs R; Semagacestat Study Group. Doody RS, et al. Among authors: mohs r. N Engl J Med. 2013 Jul 25;369(4):341-50. doi: 10.1056/NEJMoa1210951. N Engl J Med. 2013. PMID: 23883379 Free article. Clinical Trial.
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Liu-Seifert H, Siemers E, Price K, Han B, Selzler KJ, Henley D, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R; Alzheimer’s Disease Neuroimaging Initiative. Liu-Seifert H, et al. Among authors: mohs r. J Alzheimers Dis. 2015;47(1):205-14. doi: 10.3233/JAD-142508. J Alzheimers Dis. 2015. PMID: 26402769 Free PMC article. Clinical Trial.
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.
Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR Jr, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ; Alzheimer's Disease Cooperative Study. Grundman M, et al. Among authors: mohs r. Arch Neurol. 2004 Jan;61(1):59-66. doi: 10.1001/archneur.61.1.59. Arch Neurol. 2004. PMID: 14732621 Clinical Trial.
Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's disease.
Doody RS, Raman R, Sperling RA, Seimers E, Sethuraman G, Mohs R, Farlow M, Iwatsubo T, Vellas B, Sun X, Ernstrom K, Thomas RG, Aisen PS; Alzheimer’s Disease Cooperative Study. Doody RS, et al. Among authors: mohs r. Alzheimers Res Ther. 2015 Jun 10;7(1):36. doi: 10.1186/s13195-015-0121-6. eCollection 2015. Alzheimers Res Ther. 2015. PMID: 26064192 Free PMC article.
Randomized controlled trials in mild cognitive impairment: Sources of variability.
Petersen RC, Thomas RG, Aisen PS, Mohs RC, Carrillo MC, Albert MS; Alzheimer's Disease Neuroimaging Initiative (ADNI) and Foundation for NIH (FNIH) Biomarkers Consortium AD MCI Placebo Data Analysis Project Team. Petersen RC, et al. Neurology. 2017 May 2;88(18):1751-1758. doi: 10.1212/WNL.0000000000003907. Epub 2017 Apr 5. Neurology. 2017. PMID: 28381516 Free PMC article.
269 results